Latest Conference Articles

Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.

Alexandra M. Miller, MD, discusses whole genome sequencing of cerebrospinal fluid circulating tumor DNA for tracking clonal evolution in high-grade glioma.

Balazs Halmos, MD, explains how frontline combinations, new later-line choices, and side effect management are reshaping care in EGFR-mutated lung cancer.

Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.

Theodore S. Johnson, MD, PhD, discusses immune activation and survival with indoximod plus temozolomide in recurrent ependymoma.

Benjamin Bleiberg, MD, explains how toxicity guides first-line care in EGFR-mutant NSCLC and previews ADCs in small cell lung cancer.

Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.

Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.

Patrick Forde, MBBCh, PhD, explains why circulating tumor DNA testing falls short after lung cancer surgery and previews vaccine and KRAS G12C trials.

Patrick Forde, MBBCh, PhD, explains how he sequences neoadjuvant and adjuvant osimertinib and why genomic testing matters before lung cancer surgery.

Patrick Forde, MBBCh, PhD, explains how pathological complete response guides his decision to add adjuvant immunotherapy in resectable lung cancer.

Paolo Tarantino, MD, PhD, and Ying Fan, MD, compare breast cancer care in the US and China and discuss HORIZON-Breast06 and PANKU-Breast01.

Li Zhang, MD, discusses OptiTROP-Lung04 and PANKU-Lung01, choosing between sac-TMT and iza-bren, and ADC practice in China and the US.

Martin Gleave, MD, FRCSC, FACS, discussed selecting patients with high-risk prostate cancer for systemic therapy combined with surgery.

Jeremie Calais, MD, PhD, discussed how biomarkers, disease aggressiveness, and patient preferences informed PSMA-targeted therapy sequencing.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.

Jeremie Calais, MD, PhD, discussed tailoring PSMA-targeted therapy sequencing and treatment delivery to disease features and response.

Seth A. Wander, MD, PhD, discusses new first-line and maintenance therapy options and resistance to T-DXd in HER2-positive metastatic breast cancer.

Benjamin P. Levy, MD, explains the rationale for dual EGFR and HER3 targeting with iza-bren and the open sequencing questions after osimertinib.

Benjamin P. Levy, MD, explains how patient factors, TP53 co-mutations, and brain metastases guide his first-line choices in EGFR-mutant lung cancer.

Benjamin P. Levy, MD, discusses how osimertinib-based and amivantamab-based combinations are reshaping first-line care for EGFR-mutated non-small cell lung cancer.

Tiffany A. Traina, MD, FASCO, discusses incorporating T-DXd and biomarkers into early-stage HER2-positive breast cancer treatment.

Patrick Borgen, MD, discusses the importance of treatment decision-making based on HER2 biology and the surgeon’s role in HER2-positive disease management.

Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.

Sara Nunnery, MD, MSCI, discusses genomic testing, ovarian function suppression, and toxicity management in hormone receptor–positive breast cancer.

Kelsey H. Natsuhara, MD, discusses emerging ADCs and the importance of clinical trial enrollment in triple-negative breast cancer.

Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.

Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.

Floor Backes, MD, discusses BEHOLD-1 data for the B7-H4–directed ADC mocertatug rezetecan in platinum-resistant ovarian cancer.